The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study
Abstract
Objective: Induction of malignancy is a major concern when rheumatoid arthritis (RA) is treated with biologic therapy. A meta‐analysis of RA biologic clinical trials found a general increased risk of malignancy, but this risk was not found in a large observational study. We undertook this study to assess the risk of malignancy among biologic‐treated patients in a large US observational database. Methods: We studied incident cases of cancer among 13,001 patients during ∼49,000 patient‐years of observation in the years 1998–2005. Cancer rates were compared with population rates using the US National Cancer Institute SEER (Surveillance, Epidemiology, and End‐Results) database. Assessment of the risk of biologic therapy utilized conditional logistic regression to calculate odds ratios (ORs) as estimates of the relative risk, further adjusted for 6 confounders: age, sex, education level, smoking history, RA severity, and prednisone use. Results: Biologic exposure was 49%. There were 623 incident cases of nonmelanotic skin cancer and 537 other cancers. The standardized incidence ratios and 95% confidence intervals (95% CIs) compared with SEER data were as follows: all cancers 1.0 (1.0–1.1), breast 0.8 (0.6–0.9), colon 0.5 (0.4–0.6), lung 1.2 (1.0–1.4), lymphoma 1.7 (1.3–2.2). Biologics were associated with an increased risk of nonmelanotic skin cancer (OR 1.5, 95% CI 1.2–1.8) and melanoma (OR 2.3, 95% CI 0.9–5.4). No other malignancy was associated with biologic use; the OR (overall risk) of any cancer was 1.0 (95% CI 0.8–1.2). Conclusion: Biologic therapy is associated with increased risk for skin cancers, but not for solid tumors or lymphoproliferative malignancies. These associations were consistent across different biologic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Klareskog, L., Stolt, P., Lundberg, K., Källberg, H., Bengtsson, C., Grunewald, J., Rönnelid, J., Erlandsson Harris, H., Ulfgren, A., Rantapää‐Dahlqvist, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21575 · Cited by 1,515
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.
Fries, J. F., Spitz, P. W., & Young, D. Y. (1982) · PubMed · Cited by 1,318
Cancer after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D. T., & Wang, C. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00450.x · Cited by 1,071
Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I., Rosenquist, R., Feltelius, N., Sundström, C., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21675 · Cited by 890
Jensen, P., Hansen, S., Møller, B., Leivestad, T., Pfeffer, P., Geiran, O., Fauchald, P., & Simonsen, S. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70185-4 · Cited by 871
INCIDENCE OF SKIN CANCER AFTER RENAL TRANSPLANTATION IN THE NETHERLANDS
HARTEVELT, M. M., BAVINCK, J. N. B., KOOTTE, A. M. M., VERMEER, B. J., & VANDENBROUCKE, J. P. (1990) · Transplantation · doi:10.1097/00007890-199003000-00006 · Cited by 694
Wolfe, F., & Michaud, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20311 · Cited by 644
Self-citationThe prevalence and meaning of fatigue in rheumatic disease.
Wolfe, F., Hawley, D. J., & Wilson, K. (1996) · PubMed · Cited by 641
Self-citation
Cited by
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Gabriel, S. E., & Michaud, K. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2669 · Cited by 891
Self-citationGuidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 769
Burmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J., & Lacerda, A. P. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201244 · Cited by 591
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
Simon, T. A., Thompson, A., Gandhi, K. K., Hochberg, M. C., & Suissa, S. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0728-9 · Cited by 557
Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
Long, M. D., Martin, C. F., Pipkin, C. A., Herfarth, H. H., Sandler, R. S., & Kappelman, M. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.004 · Cited by 526
Cameron, M. C., Lee, E., Hibler, B. P., Barker, C. A., Mori, S., Cordova, M., Nehal, K. S., & Rossi, A. M. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.060 · Cited by 525
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
Smitten, A. L., Simon, T. A., Hochberg, M. C., & Suissa, S. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2404 · Cited by 474
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D. A., Finlay, A. Y., Griffiths, C. E. M., Jackson, K., McHugh, N. J., et al. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09505.x · Cited by 464
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A., Koo, J. Y. M., Lebwohl, M., Leonardi, C. L., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.055 · Cited by 460
Kremer, J., Li, Z.-G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., Isaacs, J. D., Gruben, D., Wallenstein, G., Krishnaswami, S., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00006 · Cited by 448
Nam, J. L., Winthrop, K. L., van Vollenhoven, R. F., Pavelka, K., Valesini, G., Hensor, E. M. A., Worthy, G., Landewé, R., Smolen, J. S., Emery, P., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126573 · Cited by 406
Mariette, X., Matucci-Cerinic, M., Pavelka, K., Taylor, P., van Vollenhoven, R., Heatley, R., Walsh, C., Lawson, R., Reynolds, A., & Emery, P. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.149419 · Cited by 404
Comorbidities in rheumatoid arthritis
Michaud, K., & Wolfe, F. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.06.002 · Cited by 400
Self-citationMarsden, J. R., Newton-Bishop, J. A., Burrows, L., Cook, M., Corrie, P. G., Cox, N. H., Gore, M. E., Lorigan, P., MacKie, R., Nathan, P., et al. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09883.x · Cited by 396
Cohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., Winthrop, K. L., Charles-Schoeman, C., Thirunavukkarasu, K., DeMasi, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210457 · Cited by 393
van Vollenhoven, R. F., Emery, P., Bingham, C. O., Keystone, E. C., Fleischmann, R. M., Furst, D. E., Tyson, N., Collinson, N., & Lehane, P. B. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201956 · Cited by 390
Psoriasis: Which therapy for which patient
Kaushik, S. B., & Lebwohl, M. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.057 · Cited by 368
Integrated safety in tocilizumab clinical trials
Schiff, M. H., Kremer, J. M., Jahreis, A., Vernon, E., Isaacs, J. D., & van Vollenhoven, R. F. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3455 · Cited by 367
Leombruno, J. P., Einarson, T. R., & Keystone, E. C. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091025 · Cited by 362
BYKERK, V. P., AKHAVAN, P., HAZLEWOOD, G. S., SCHIEIR, O., DOOLEY, A., HARAOUI, B., KHRAISHI, M., LECLERCQ, S. A., LÉGARÉ, J., MOSHER, D. P., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.110207 · Cited by 335
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Askling, J., Fahrbach, K., Nordstrom, B., Ross, S., Schmid, C. H., & Symmons, D. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2046 · Cited by 301
Lopez-Olivo, M. A., Tayar, J. H., Martinez-Lopez, J. A., Pollono, E. N., Cueto, J. P., Gonzales-Crespo, M. R., Fulton, S., & Suarez-Almazor, M. E. (2012) · JAMA · doi:10.1001/2012.jama.10857 · Cited by 295
Rubbert-Roth, A., & Finckh, A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2666 · Cited by 266
Strangfeld, A., Hierse, F., Rau, R., Burmester, G.-R., Krummel-Lorenz, B., Demary, W., Listing, J., & Zink, A. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2904 · Cited by 264
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Wolfe, F., & Michaud, K. (2009) · Arthritis Care & Research · doi:10.1002/art.24428 · Cited by 171
Self-citation
Metadata
- Authors
- Wolfe, F., & Michaud, K.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-08-29
- Volume
- 56
- Issue
- 9
- Pages
- 2886-2895
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2028672514
- Cited by
- 534
- References
- 36
- FWCI
- 29.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.